Compare · NYXH vs RMD
NYXH vs RMD
Side-by-side comparison of Nyxoah SA (NYXH) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYXH and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $32.03B, about 246.1x NYXH ($130.1M).
- Over the past year, NYXH is down 49.8% and RMD is down 6.1% - RMD leads by 43.7 points.
- RMD has hit the wire 2 times in the past 4 weeks while NYXH has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 8 for NYXH).
- Company
- Nyxoah SA
- ResMed Inc.
- Price
- $2.98-2.93%
- $219.82+0.11%
- Market cap
- $130.1M
- $32.03B
- 1M return
- -5.85%
- -2.86%
- 1Y return
- -49.83%
- -6.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 2
- Recent ratings
- 8
- 25
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NYXH
- SEC Form S-8 filed by Nyxoah SA
- SEC Form 20-F filed by Nyxoah SA
- Publication relating to transparency notifications
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Publication relating to transparency notification
- Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
- Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
- Publication relating to transparency notifications
- Information on the total number of voting rights and shares
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.